Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know

By David Jagielski, CPA – Feb 10, 2026 at 1:00PM ESTKey PointsThe growth potential in the GLP-1 market could help healthcare stocks soar in value.Competition, however, is likely to be fierce.Many drugs offer comparable weight loss.We’re bullish on these 10 stocks ›NYSE: LLYEli LillyMarket Cap$988BToday's Changeangle-down(-1.01%) $10.55Current Price$1034.12Price as of February 10, 2026 at 1:44 PM ETThe GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it.Healthcare companies have been feverishly working on developing GLP-1 weight loss products in an effort to cash in on what's turning out to be a massive gold rush in the sector. Companies big and small have GLP-1 drug candidates in development that, if successful, could be game changers for their businesses. It could put small stocks on the map, and for larger companies, it could mean an improvement in their growth rates. It may seem exciting to invest in GLP-1 stocks for their future growth potential, but there are important things to consider before you dive in. Here are three key things you should know about GLP-1 stocks, to help you decide whether it can be a good area for you to invest in. Image source: Getty Images. The market is massive, but estimates have been coming down Given the potential for weight loss drugs to improve the overall health of patients and their wide-ranging benefits, analysts have been understandably bullish on the space. But perhaps they have been too excited about it. Goldman Sachs recently trimmed its forecast for the anti-obesity drug market. It projects that the global market will be worth $95 billion by the end of the decade, which is a sizable decrease from the $130 billion it was previously forecasting. It's still massive, but it's a sign of just how much hype there has been around GLP-1 drugs. And with concerns about side effects and people gaining weight back after they stop using the drugs, it's possible there may still be too much hype right now. Competition is likely to ramp up Today, Eli Lilly (LLY 1.01%) looks to be the early leader in the GLP-1 space, as it has been experiencing tremendous growth. Its valuation is around the $1 trillion mark as its effective GLP-1 drugs have enabled it to generate fantastic results and attract many growth investors in the process. Meanwhile, it hopes to have an approved pill later this year, which could enhance its growth prospects even further. ExpandNYSE: LLYEli LillyToday's Change(-1.01%) $-10.55Current Price$1034.12Key Data PointsMarket Cap$988BDay's Range$1029.00 - $1055.7352wk Range$623.78 - $1133.95Volume88KAvg Vol3.5MGross Margin85.40%Dividend Yield0.57% But the big question is how well its growth will hold up in the future, as other GLP-1 drugs inevitably enter the market. Pfizer, Roche, and other big names in healthcare have invested in GLP-1 drugs and could have products of their own that may take market share in the not-too-distant future. The end result may be a potentially fragmented market. The preferred GLP-1 drug may be the one with the fewest side effects Many GLP-1 drugs that are approved and in development offer comparable weight loss, often in the neighborhood of 15% to 20%. That's why investors should pay close attention to drugs that have the least concerning side effects, and that may be most tolerable for patients, as those could prove to be the biggest winners in the market. If you're unsure of which GLP-1 stocks to buy, the safest option may be to go with either Eli Lilly or Novo Nordisk, which are already big players today and which have approved GLP-1 drugs in their respective portfolios.Read NextFeb 10, 2026 •By Reuben Gregg BrewerEli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.Feb 10, 2026 •By Adria CiminoCould Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?Feb 9, 2026 •By David Jagielski, CPANovo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment?Feb 9, 2026 •By David Jagielski, CPAOver 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs.

Should Investors Be Worried?Feb 9, 2026 •By Rich SmithWhy Eli Lilly Stock Just PoppedFeb 8, 2026 •By Geoffrey SeilerEli Lilly Shares Surge on Weight-Loss Drug Momentum.

Is It Time to Buy the Stock?About the AuthorDavid Jagielski, CPA, has been a contributing Motley Fool stock market analyst covering healthcare, consumer staples, consumer discretionary, and technology stocks since 2017. David has more than 10 years of experience in finance roles across businesses of different sizes and sectors. He holds a Certified Public Accountant designation in Canada.TMFdjagielskiStocks MentionedEli LillyNYSE: LLY$1034.12 (1.01%) $10.55Goldman Sachs GroupNYSE: GS$933.83 (1.04%) $9.79PfizerNYSE: PFE$27.57 (+1.92%) $+0.52Roche Holding AGOTC: RHHBY$56.98 (0.23%) $0.13Novo NordiskNYSE: NVO$49.35 (0.04%) $0.02*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.